Brand Recall Hub
Taro Recalls in Canada
15 recalls found for Taro. Data sourced from Health Canada, CFIA, and Transport Canada. Updated daily.
15 Taro Recalls
TARO-CANDESARTAN: Affected lots were manufactured using an active ingredient that was out of specification for dissolution
Product quality
View recall details →
Taro-Doxorubicin Liposomal: may contain particulate matter
Product quality
View recall details →
TARO-GLICLAZIDE MR: may contain the presence of pink coloured stain (identified as Candesartan Cilexetil)
Product safety
View recall details →
Taro-Dipyridamole/ASA: impurity
Product quality
View recall details →
Esomeprazole, Candesartan and Pravastatin Tablets: OOS result for Finished Product Assay and/or Blend Uniformity
Product quality
View recall details →
Venlafaxine: OOS result for Spheroids Dissolution Rate Profile (DRP)
Product quality
View recall details →
Taro-Zoledronic Acid: The affected lots may contain particulate matter
Product quality
View recall details →
Taro-Zoledronic acid injection drug, used for osteoporosis and Page's disease, recalled because it may contain particulate matter
Product quality
View recall details →
TARO-Bupropion XL (2021-09-13)
Product safety
View recall details →
Taro Pharmaceuticals Inc. Product Recall (2020-11-17)
Product safety
View recall details →
Taro Pharmaceuticals Inc. Product Recall (2020-07-20)
Product safety
View recall details →
Certain Lots of Taro-Zoledronic acid injection drug, used for osteoporosis and Paget's disease, recalled due to potential presence of particulate matter
View recall details →
Taro-Zoledronic Acid (2020-03-30)
Product safety
View recall details →
Taro-Carbamazepine (2020-01-29)
Product safety
View recall details →
Taro-Tramadol 300mg Tablet (2018-09-17)
Product safety
View recall details →